Literature DB >> 34738046

Recent Advances in Gene Therapy for Cancer Theranostics.

Hannah J Vaughan1, Jordan J Green1,2.   

Abstract

There is great interest in developing gene therapies for many disease indications, including cancer. However, successful delivery of nucleic acids to tumor cells is a major challenge, and in vivo efficacy is difficult to predict. Cancer theranostics is an approach combining anti-tumor therapy with imaging or diagnostic capabilities, with the goal of monitoring successful delivery and efficacy of a therapeutic agent in a tumor. Successful theranostics must maintain a high degree of anticancer targeting and efficacy while incorporating high-contrast imaging agents that are nontoxic and compatible with clinical imaging modalities. This review highlights recent advancements in theranostic strategies, including imaging technologies and genetic engineering approaches. Graphical Abstract.

Entities:  

Year:  2021        PMID: 34738046      PMCID: PMC8562678          DOI: 10.1016/j.cobme.2021.100300

Source DB:  PubMed          Journal:  Curr Opin Biomed Eng        ISSN: 2468-4511


  110 in total

1.  Tumor heterogeneity and personalized medicine.

Authors:  Dan L Longo
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

Review 2.  Antibody-Gold Nanoparticle Bioconjugates for Biosensors: Synthesis, Characterization and Selected Applications.

Authors:  Lu Zhang; Yacine Mazouzi; Michèle Salmain; Bo Liedberg; Souhir Boujday
Journal:  Biosens Bioelectron       Date:  2020-06-20       Impact factor: 10.618

Review 3.  Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications.

Authors:  Seyed Mohammadali Dadfar; Karolin Roemhild; Natascha I Drude; Saskia von Stillfried; Ruth Knüchel; Fabian Kiessling; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2019-01-11       Impact factor: 15.470

Review 4.  Cancer gene therapy targeting cellular apoptosis machinery.

Authors:  Lin-Tao Jia; Si-Yi Chen; An-Gang Yang
Journal:  Cancer Treat Rev       Date:  2012-07-15       Impact factor: 12.111

5.  Protein-based MRI contrast agents for molecular imaging of prostate cancer.

Authors:  Lixia Wei; Shunyi Li; Jianhua Yang; Yiming Ye; Jin Zou; Liya Wang; Robert Long; Omar Zurkiya; Tiejun Zhao; Julian Johnson; Jingjuan Qiao; Wangda Zhou; Adriana Castiblanco; Natalie Maor; Yanyi Chen; Hui Mao; Xiaoping Hu; Jenny J Yang; Zhi-Ren Liu
Journal:  Mol Imaging Biol       Date:  2011-06       Impact factor: 3.488

6.  Radioisotope concentrator gene therapy using the sodium/iodide symporter gene.

Authors:  R B Mandell; L Z Mandell; C J Link
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

Review 7.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

8.  High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice.

Authors:  Jin Hee Kim; Sang-Rok Lee; Li-Hua Li; Hye-Jeong Park; Jeong-Hoh Park; Kwang Youl Lee; Myeong-Kyu Kim; Boo Ahn Shin; Seok-Yong Choi
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer.

Authors:  Kenneth N Barton; Farzan Siddiqui; Robert Pompa; Svend O Freytag; Gazala Khan; Irina Dobrosotskaya; Munther Ajlouni; Yingshu Zhang; Jingfang Cheng; Benjamin Movsas; David Kwon
Journal:  Mol Ther Oncolytics       Date:  2020-12-03       Impact factor: 7.200

10.  Sclerosing angiomatoid nodular transformation of the spleen: CT, MR, PET, and ⁹⁹(m)Tc-sulfur colloid SPECT CT findings with gross and histopathological correlation.

Authors:  Curtis Thacker; Ronald Korn; John Millstine; Howard Harvin; Jeffrey A Van Lier Ribbink; Michael B Gotway
Journal:  Abdom Imaging       Date:  2010-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.